
ACCINEX

Results of phase 2 SIGNAL trial of the SEMA4D blocking antibody suggest pepinemab is a novel potential treatment for neurodegenerative disease

T. Fisher¹, E. Evans¹, A. Reader¹, V. Mishra¹, C. Mallow¹, L. Balch¹, A. Howell¹, E. Smith¹, J. Leonard¹, A. Feigin², E. Siemers³, J. Wittes⁴ M. Zauderer¹. ¹ Vaccinex, Inc.; ² for the Huntington Study Group, and SIGNAL investigators and coordinators; ³ Siemers Integration LLC; ⁴ for Statistics Collaborative



Glial cells respond to damage induced by mutant Huntingtin protein and other neurotoxins

SEMA4D is upregulated during disease progression


Chronic reactive gliosis and inflammation exacerbates neurodegeneration

Blocking SEMA4D can reduce neurodegenerative processes in preclinical models



SIGNAL: randomized placebo controlled trial in subjects with early HD





Study Objectives

- Safety and tolerability
- Clinical global impression of change (CGIC) and Cognitive Function measures
- Brain imaging measures



Abbreviated Safety and Baseline Characteristics Cohort B1 and B2, ITT population



Pepinemab (PEPI) SEMA4D blocking antibody is well tolerated

	Cohort B1	L (N=179)	Cohort B2 (N=86)		
	PBO (N=88)	PEPI (N=91)	PBO (N=45)	PEPI (N=41)	
Discontinued Treatment Early	10	13	2	0	
Had Any SAE (*)	8	4	4	2	
Had Any Grade 3+ AE (*)	14	17	6	8	
CAG repeat length	44.1 (3.8)	43.5 (3.1)	42.8 (2.3)	42.4 (2.7)	
CAP score (**)	470 (96)	466 (85)	374 (72)	404 (98)	
UHDRS-DCL at screening, n(%)					
0,1 –Normal or non-specific signs	0	0	0	0	
2 – May be HD (50%-89% confident)	0	0	31 (69%)	29 (71%)	
3 – Likely HD (90%-98% confident	0	0	14 (31%)	12 (29%)	
4 –Unequivocal HD (>99% confident)	88 (100%)	91 (100%)	0	0	


*pre-COVID era; **CAP score = age × (CAG repeat length – 33.66)



Cognitive Assessment Co-Primary 1a: Test of Planning and Memory Co-Primary 1b: Test of Timing and Processing Speed




1a: One Touch Stockings	One-sided p-value	Favors PEPI	Success [Critical value]
Early Manifest HD	0.028	Yes	No [0.025] [0.0125]



1b:	Paced	Finger
Та	pping	Task

Early Manifest HD

One-sided p-value	Favors PEPI	Success [Critical value]
0.06	Yes	No [0.025] [0.0125]






Cognitive Assessment Battery: Prespecified Exploratory analysis, HD-CAB Composite Score



HD-CAB Composite Index of 6 Cognitive Assessments

Early manifest HD



One- sided p- value	Favors PEPI	Critical value
0.007	Yes	Yes [0.025]



Cognitive Assessment Battery: Prespecified Exploratory analysis, HD-CAB Composite Score

HD-CAB Index (Cohort B2 reference)ⁱ



			PBO		PEPI	Difference,	PEPI - PBO
	Population / Parameter	N ^a	Mean (SE)	N ^a	Mean (SE)	Estimate (95% CI)	One-Sided p-value (+ Favors PEPI) ^b
	Cohort B1 mITT (N=178)	88		90			
B1. Early Manifest	OTS (sec) ^c	88	-0.33 (0.72)	89	-2.30 (0.73)	-1.98 (-4.00, 0.05)	0.028 (+)
	PTAP $(1/\text{sec})^d$	87	-1.67 (0.65)	89	-0.24 (0.64)	1.43 (-0.37, 3.23)	0.060 (+)
	SDMT ^e	88	-3.59 (0.70)	89	-2.97 (0.71)	0.62 (-1.35, 2.59)	0.27 (+)
	EMO ^f	88	-0.09 (0.33)	89	0.28 (0.33)	0.37 (-0.55, 1.30)	0.22 (+)
	HVLT-R ^g	88	0.21 (0.73)	89	0.65 (0.73)	0.44 (-1.59, 2.47)	0.34 (+)
	TMT-B (sec) ^h	88	8.27 (4.24)	89	1.06 (4.26)	-7.21 (-19.09, 4.66)	0.12 (+)
	HD-CAB Index (Cohort B1 reference) ⁱ	87	-0.12 (0.04)	89	0.01 (0.04)	0.13 (0.03, 0.23)	0.007 (+)
		РВО		BO PEPI		Difference, PEPI - PBO	
	Population / Parameter	$\mathbf{N}^{\mathbf{a}}$	Mean (SE)	Nª	Mean (SE)	Estimate (95% CI)	One-Sided p-value (+ Favors PEPI) ^b
	Cohort B2 mITT (N=86)	45		41			
B2.	OTS (sec) ^c	44	-0.89 (0.74)	41	-0.94 (0.74)	-0.05 (-2.14, 2.05)	0.49 (+)
				-11	(0.71)	0.00 (2.11, 2.00)	0.12 (1)
	PTAP $(1/sec)^d$	44	0.08 (1.02)	41	-1.00 (1.04)	-1.08 (-3.98, 1.82)	0.77 (-)
B2. Prodromal							
	PTAP (1/sec) ^d	44	0.08 (1.02)	41	-1.00 (1.04)	-1.08 (-3.98, 1.82)	0.77 (-)
	PTAP (1/sec) ^d SDMT ^e	44 45	0.08 (1.02) 1.07 (1.05)	41 41	-1.00 (1.04) -0.29 (1.09)	-1.08 (-3.98, 1.82) -1.36 (-4.38, 1.65)	0.77 (-) 0.82 (-)
	PTAP (1/sec) ^d SDMT ^e EMO ^f	44 45 44	0.08 (1.02) 1.07 (1.05) 0.35 (0.47)	41 41 41	-1.00 (1.04) -0.29 (1.09) -0.42 (0.47)	-1.08 (-3.98, 1.82) -1.36 (-4.38, 1.65) -0.77 (-2.09, 0.55)	0.77 (-) 0.82 (-) 0.88 (-)

MMRM analysis of HD-CAB Month 17 change from baseline in Early Manifest (B1) and Prodromal (B2) Subjects

41

0.08 (0.06)

-0.11 (-0.27, 0.06)

0.90 (-)

0.18 (0.06)

44



CGIC Post-hoc Subgroup Analysis – Early Manifest HD



Subjects were less likely to experience decline in CGIC following treatment with pepinemab compared to placebo.

This difference was evident in subjects with somewhat more advanced disease (TFC 11).


CGIC – Subjects with CGIC – Subjects with **Baseline UHDRS TFC 11** Baseline UHDRS TFC 12 and 13 49 54 51 53 30 27 28 25 P=0.041* Improve Improve Worsen Worsen 71 44 % 47 45 % PBO PEPI PBO PEPI PBO PEPI PBO PEPI Month 11 Month 17 Month 11 Month 17

Very much worse
Much worse
Minimally worse
No change
Minimally improved
Much improved

*nominal one-sided p-value, Fisher's exact test for worsening score


FDG-PET at 18 Months Pepinemab treatment reverses loss of metabolic activity





<u>ACCÍNEX</u>

FDG-PET Difference in % Change SUVR (PEPI-PBO) Early Manifest at Visit18




8






volumetric MRI analysis – Boundary Shift Integral Pre-specified exploratory endpoint

CBSI (caudate atrophy) Early Manifest (B1)



VBSI (ventricular expansion) Early Manifest (B1)









Pepinemab and sSEMA4D levels in cerebrospinal fluid (CSF)

Most subjects dosed with pepinemab have ≥ saturating levels (100-300 ng/ml) in CSF



Pepinemab : sSEMA4D complex increases in subjects dosed with pepinemab – suggesting target engagement



Summary

- HYPOTHESIS: treatment with anti-SEMA4D MAb pepinemab will prevent hypometabolism and inflammatory pathology and restore or delay cognitive loss
 - MOA: SEMA4D is upregulated during disease progression. Antibody blockade of SEMA4D preserves normal astrocyte functions and prevents glial transition to inflammatory activity
 - This mechanism of action is believed to be applicable to neurodegenerative diseases including HD and AD
- SIGNAL-HD, a Phase2 study in subjects with prodromal and early manifest HD
 - Pepinemab was well-tolerated and was shown to cross the BBB at the anticipated level of 0.1% or greater of circulating antibody
 - Reduced deteriorating CGIC in subjects with more advanced TFC11 (p=0.04)
 - Treatment benefit observed in the HD-CAB cognitive battery (p=0.007)
 - Reduced brain atrophy (vMRI) and slowed or reversed decline in metabolic activity (FDG-PET)
 - Treatment benefits were detected in patients with more advanced disease (EM and TFC11)
- SIGNAL-AD, a Phase 1b/2a study in AD, is planned to begin enrollment in 2021
- > A Phase 3 trial of pepinemab in HD is in the protocol design stage